65,437 trials
Multiple Myeloma
Primary: Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response — 8; 7 participants — p=1.0000
Hepatitis C, Chronic
Primary: Time to Premature Treatment Discontinuation Due to Any Reason — 40.0; 40.6 weeks — p=0.6451
Actinic Keratosis
Primary: Treatment Success at End of Study Visit — 66.7; 65.2; 76.0; 66.7 percentage of participants — p=0.799
Breast Cancer
Primary: Mammographic Density — 22.71; 21.84; 22.09; 21.13 Percent
Chronic Hepatitis C Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses — 97.1; 82.4; 98.8; 97.6 percentage of…
Intraocular Pressure
Primary: Measurement of Intraocular Pressure — 15.9; 16.0; 16.9 mm Hg
Myocardial Infarction
Primary: Non-adherence Score — 16.6; 22.8 Non-adherence score — p=0.025
Breast Cancer
Primary: Time to Disease Progression (TDP) — 15.3 months
Parkinson's Disease
Primary: Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III at Week 30 — -0.6; -11.7; -12.9; -14.9 units on a scale
Breast Cancer
Primary: Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E) — 16.7; 12.5; 0.0; 8.3 percentage of participants
Leukemia · Lymphoma
Primary: Complete Remission (CR) — 50; 50; 14; 11 participants
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
Rheumatoid Arthritis
Primary: DAS28 Score — 5.3; 5.0; 5.4; 4.8 units on a scale
Gastric Cancer
Primary: Percentage of Participants Who Are Progression-Free at 12 Weeks (Progression-Free Survival [PFS] Rate at 12 Weeks) — 23.8 Percentage of Participants
Anesthesia
Primary: Percentage of Patients With Successful Epidural Blocks — 76; 98 percentage of patients